Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861741 | 0.78 | MAPK1 (0.35) | MAPK1DGAT1MEN1KMT2A | |
| SCHEMBL14276378 | 0.78 | MAPK1 (0.35) | MAPK1DGAT1MEN1KMT2A | |
| SCHEMBL10329704 | 0.78 | MAPK1 (0.35) | MAPK1DGAT1MEN1KMT2A | |
| SCHEMBL29031931 | 0.78 | MAPK1 (0.35) | MAPK1DGAT1MEN1KMT2A | |
| SCHEMBL11794957 | 0.75 | LMNA (0.31) | — | |
| SCHEMBL14616414 | 0.75 | LMNA (0.39) | MAPK1MEN1KMT2A | |
| SCHEMBL1150592 | 0.75 | LMNA (0.39) | MAPK1MEN1KMT2A | |
| SCHEMBL1150593 | 0.75 | LMNA (0.39) | MAPK1MEN1KMT2A | |
| SCHEMBL2127159 | 0.75 | NR1H2 (0.33) | MAPK1 | |
| SCHEMBL11231868 | 0.75 | LMNA (0.39) | MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6469198-B2 | OBTAINED BY CONTACTING N-SALICYLIDENEAMINOALCOHOL WITH MONO OR DIVALENT COPPER COMPOUND; FORMATION OF OPTICALLY ACTIVE CYCLOPROPANE-CARBOXYLIC ESTER FROM PROCHIRAL OLEFIN AND DIAZOACETIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-22 | — | — | US | disclosed |
| US-20010037036-A1 | Chiral copper complex catalyst composition and asymmetric production process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-11-01 | — | — | US | disclosed |
| EP-1120401-A2 | Chiral copper complex catalyst composition and asymmetric production process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037036-A1 | Chiral copper complex catalyst composition and asymmetric production process using the same | AP1M1, UBA3, AP1S1 | MAPK1 1023/4885HRH3 2062/4885DGAT1 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.